🔎 Trials Near Me

Home › Ovarian Cancer › Pennsylvania › Philadelphia

Ovarian Cancer clinical trials in Philadelphia, PA

44 studies for Ovarian Cancer are looking for participants at sites in and around Philadelphia (within about 30 miles). Open a study to see who can join and how to contact the study team.

Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

RecruitingPhase 2/3
  • Thomas Jefferson University Hospital, Philadelphia
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT07001748

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

RecruitingPhase 2
  • Pennsylvania Hospital, Philadelphia
  • Thomas Jefferson University Hospital, Philadelphia
  • Fox Chase Cancer Center, Philadelphia
  • and 4 more
All ages · All sexes · Updated Oct 5, 2026 · NCT05564377

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

RecruitingPhase 1/2
  • Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT04585750

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

RecruitingPhase 1
  • Sidney Kimmell Cancer Center - Jefferson Health, Philadelphia
Ages 19 and older · All sexes · Updated Oct 1, 2026 · NCT06586957

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

RecruitingPhase 2
  • Site 0232 - University of Pennsylvania, Philadelphia
  • Site 0178 - Thomas Jefferson University, Philadelphia
Ages 18 and older · Women · Updated Sep 29, 2026 · NCT05128825

Study of AVZO-021 in Patients With Advanced Solid Tumors

RecruitingPhase 1/2
  • Avenzo Therapeutics Recruiting Site, Philadelphia
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05867251

DESTINY-PANTUMOUR04

RecruitingObservational study
  • Research Site, Philadelphia
Ages 18 to 130 · All sexes · Updated Sep 25, 2026 · NCT07124000

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

RecruitingPhase 1/2
  • Perelman School of Medicine at the University of Pennsylvania, Philadelphia
Ages 18 and older · Women · Updated Sep 24, 2026 · NCT04590326

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

RecruitingPhase 3
  • University of Pennsylvania Hospital, Philadelphia
  • Jefferson Health Honickman Center, Philadelphia
  • Asplundh Cancer Pavilion, Willow Grove · 13 mi away
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07213804

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

RecruitingPhase 1
  • University of Pennsylvania, Philadelphia
  • Fox Chase Cancer Center, Philadelphia
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07213791

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

RecruitingPhase 2
  • Penn Medicine University of Pennsylvania Health System /ID# 277963, Philadelphia
Ages 18 and older · Women · Updated Sep 22, 2026 · NCT07059845

Prehabilitation in High-risk Oncologic Surgery

Recruiting
  • Fox Chase Cancer Center - Philadelphia, Philadelphia
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT07638410

BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

RecruitingPhase 1/2
  • University of Pennsylvania, Philadelphia
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT04752826

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

RecruitingPhase 3
  • Hospital of the University of Pennsylvania ( Site 0071), Philadelphia
Ages 18 and older · Women · Updated Sep 17, 2026 · NCT07318558

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

RecruitingPhase 3
  • Lankenau Medical Center, Wynnewood · 7 mi away
Ages 18 and older · Women · Updated Sep 15, 2026 · NCT07214779

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

RecruitingObservational study
  • University of Pennsylvania, Philadelphia
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT05059444

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

RecruitingPhase 1
  • Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT07216105

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

RecruitingPhase 1/2
  • Children's Hospital of Philadelphia, Philadelphia
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

RecruitingPhase 1
  • Sidney Kimmel Comprehensive Center at Jefferson, Philadelphia
Ages 18 and older · All sexes · Updated Aug 21, 2026 · NCT06774963

A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

RecruitingPhase 1
  • SCRI - Sydney Kimmel Cancer Center - Jefferson Health, Philadelphia
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT07470853

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

RecruitingPhase 1
  • Normunity Investigational Site, Philadelphia
  • Normunity Investigational Site, Philadelphia
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT07182149

The Appendix Cancer PMP Research Foundation Natural History Study/Patient Registry

RecruitingObservational study
  • ACPMP, Springfield · 8 mi away
All ages · All sexes · Updated Aug 17, 2026 · NCT07769346

A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

RecruitingPhase 3
  • Site 0109, Philadelphia
  • Site 0113, Philadelphia
  • Site 0114, Willow Grove · 13 mi away
Ages 18 and older · Women · Updated Aug 12, 2026 · NCT07546500

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

Recruiting
  • University of Pennsylvania/Abramson Cancer Center, Philadelphia
  • Fox Chase Cancer Center, Philadelphia
  • Lankenau Medical Center, Wynnewood · 7 mi away
  • and 5 more
Ages 35 to 50 · Women · Updated Aug 7, 2026 · NCT04251052

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

RecruitingPhase 3
  • University of Pennsylvania/Abramson Cancer Center, Philadelphia
  • Pennsylvania Hospital, Philadelphia
  • Thomas Jefferson University Hospital, Philadelphia
  • and 5 more
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT06580314

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

RecruitingPhase 1/2
  • University of Pennsylvania / Abramson Cancer Center, Philadelphia
  • Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Research Organization, Philadelphia
Ages 18 and older · All sexes · Updated Jul 30, 2026 · NCT04657068

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

RecruitingPhase 2/3
  • Perelman School of Medicine at the University of Pennsylvania, Philadelphia
Ages 18 and older · All sexes · Updated Jul 28, 2026 · NCT06161025

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

RecruitingPhase 2
  • Thomas Jefferson University, Philadelphia
Ages 8 and older · All sexes · Updated Jul 27, 2026 · NCT05503797

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

RecruitingPhase 1
  • Investigative Site #109, Philadelphia
Ages 18 and older · All sexes · Updated Jul 23, 2026 · NCT06545942

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

RecruitingPhase 2
  • University of Pennsylvania Health System, Perelman Center for Advanced Medicine, Philadelphia
Ages 18 to 100 · Women · Updated Jul 13, 2026 · NCT05887609

SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma

RecruitingPhase 1
  • University of Pennsylvania, Philadelphia
Ages 18 and older · All sexes · Updated Jun 24, 2026 · NCT05568680

Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer

RecruitingPhase 1
  • Penn Medicine - Perelman Center for Advanced Medicine, Philadelphia
Ages 18 and older · Women · Updated May 28, 2026 · NCT06930755

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

RecruitingPhase 1/2
  • University of Pennsylvania, Perelamn Center for Advanced Medicine, Philadelphia
  • Thomas Jefferson University, Honickman Center, Philadelphia
  • Fox Chase Cancer Center, Philadelphia
Ages 18 and older · All sexes · Updated May 13, 2026 · NCT03686124

Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer

RecruitingPhase 3
  • Lankenau Medical Center/Mainline Medical Center, Wynnewood · 7 mi away
  • Jefferson Abington Hospital, Abington · 12 mi away
  • Asplundh Cancer Pavilion, Willow Grove · 13 mi away
Ages 18 and older · Women · Updated Apr 16, 2026 · NCT05659381

TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention

Recruiting
  • Hospital of the University of Pennsylvania, Philadelphia
Ages 25 to 50 · Women · Updated Apr 6, 2026 · NCT04294927

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

RecruitingPhase 1/2
  • Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center, Philadelphia
Ages 18 and older · All sexes · Updated Mar 27, 2026 · NCT06395519

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

RecruitingPhase 1
  • Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia
  • Fox Chase Cancer Center, Philadelphia
Ages 18 and older · All sexes · Updated Feb 13, 2026 · NCT06778863

Healthy Volunteers Study

RecruitingObservational studyHealthy volunteers welcome
  • Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Ages 30 to 50 · Women · Updated Feb 5, 2026 · NCT06962059

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

RecruitingPhase 2
  • University of Pennsylvania, Philadelphia
Ages 18 and older · Women · Updated Dec 23, 2025 · NCT06690775

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

RecruitingObservational study
  • Massive Bio SYNERGY-AI site, Philadelphia
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774

Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer

RecruitingPhase 2
  • University of Pennsylvania/Abramson Cancer Center, Philadelphia
Ages 18 and older · Women · Updated Oct 27, 2025 · NCT06617923

Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer

RecruitingObservational study
  • Gynecologic Oncology Group, Philadelphia
All ages · Women · Updated May 5, 2017 · NCT01000259

About Ovarian Cancer

Ovarian cancer is a cancerous tumor that forms in the tissues of an ovary. The ovaries are a pair of female reproductive glands that make eggs and female hormones.

More about Ovarian Cancer on MedlinePlus

Ovarian Cancer trials in other cities

Other studies in Philadelphia

From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.